Applied DNA Sciences Stock Surges On largest LinearDNA Contract

Applied DNA Sciences Inc (NASDAQ:APDN) received its largest single purchase order for LinearDNA valued above the mid-six figures.  The order was…
  • Applied DNA Sciences Inc (NASDAQ:APDN) received its largest single purchase order for LinearDNA valued above the mid-six figures. 
  • The order was placed under a long-standing supply agreement for the bulk manufacture of LinearDNA for a global manufacturer of in vitro diagnostics. 
  • Under the terms of the repeat order, the company will deliver quantities of LinearDNA to the customer in the current quarter, with the full order expected to be fulfilled over the subsequent three quarters.
  • Related: Applied DNA Seeks Approval For PCR-Based Monkeypox Virus Test.
  • LinearDNA is produced using an enzymatic (cell-free) manufacturing platform that eliminates the use of fermenters and bacteria required by plasmid DNA, the industry’s current manufacturing standard for DNA. 
  • LinearDNA eliminates many challenges associated with current plasmid-based DNA manufacturing and produces a DNA product without the risks of bacterial contamination and non-target DNA sequences. 
  • Price Action: APDN shares are up 62.9% at $2.02 on the last check Monday.
Total
0
Shares
Related Posts
Read More

AstraZeneca Announced Enhertu Approved in the EU for Patients With HER2-Positive Metastatic Breast Cancer Treated With One or More Prior Anti-HER2-based Regimens

Approval broadens indication for AstraZeneca and Daiichi Sankyo's Enhertu across Europe to earlier use in HER2-positive metastatic breast cancer. Based on ground-breaking DESTINY-Breast03 results in which Enhertu demonstrated a 72% reduction in the risk of disease progression or death vs. trastuzumab emtansine (T-DM1).

AZN